Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,071 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Memorial Sloan Kettering Cancer Center Clear all
Completed Phase 3 Interventional

Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy

NCT00200148
View directory record Official record
Conditions
Pancreaticoduodenectomy, Hepatectomy
Interventions
Normovolemic Hemodilution (ANH), Standard of care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 14, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

A Study of CRD3874-SI in People With Solid Tumors

NCT06021626
View directory record Official record
Conditions
Sarcoma, Merkel Cell Carcinoma
Interventions
CRD3874
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Completed Not applicable Interventional

A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients

NCT03285152
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Ketogenic Diet (KD), Standard Diet (SD)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Active, not recruiting Not applicable Interventional

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

NCT01829958
View directory record Official record
Conditions
Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
rituximab, prednisone, Geriatric Assessment
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

NCT07082868
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
Interventions
ibrutinib, Epcoritamab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

NCT00658385
View directory record Official record
Conditions
Beta Thalassemia Major, Congenital Anemias
Interventions
GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 14, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors

NCT03707340
View directory record Official record
Conditions
Breast Cancer, Hyposexual Desire Disorder
Interventions
Flibanserin Pill
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 14, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

NCT00847015
View directory record Official record
Conditions
Bladder Cancer, Urinary Bladder
Interventions
Sunitinib, Gemcitabine, cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 14, 2026, 4:53 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Development of Psychotherapeutic Interventions for Parents Who Lost a Child

NCT02153619
View directory record Official record
Conditions
Parents Who Have Lost a Child
Interventions
Meaning-Centered Grief Therapy (MCGT), Supportive Psychotherapy (SP), questionnaires assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Completed No phase listed Observational

Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue

NCT00581698
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 14, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Multiple Myeloma
Interventions
Audio Tasks
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Sexual Functioning After Primary Treatment of Ovarian Cancer

NCT00596544
View directory record Official record
Conditions
Ovarian Cancer, Sexual Dysfunction
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 14, 2026, 4:53 AM EDT
Completed No phase listed Observational

Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys

NCT01458509
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Surveys
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 14, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

NCT01419834
View directory record Official record
Conditions
Neuroblastoma
Interventions
Humanized 3F8 Monoclonal Antibody (Hu3F8)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 14, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

NCT07013565
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions
Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo)
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Yoga for Symptoms of Nerve Damage Caused by Chemotherapy

NCT03292328
View directory record Official record
Conditions
Breast Cancer, Peripheral Neuropathy, Gynecologic Cancer
Interventions
Yoga, Wait List Control
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 14, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

NCT00567229
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
rituximab, lenalidomide, microarray analysis, flow cytometry, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 14, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

NCT03093922
View directory record Official record
Conditions
Urothelial Carcinoma, Locally Advanced, Unresectable
Interventions
Atezolizumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Chicago, Ill • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

NCT01474551
View directory record Official record
Conditions
Melanoma
Interventions
vemurafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 14, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Genomic Predictors of Papillary Microcarcinoma Disease Progression

NCT02363595
View directory record Official record
Conditions
Papillary Microcarcinoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

NCT05873205
View directory record Official record
Conditions
Blood Cancer, Refractory Immune Cytopenias
Interventions
Isatuximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Completed No phase listed Observational

Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men

NCT00581672
View directory record Official record
Conditions
Prostate Cancer
Interventions
questionnaires of quality of life
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 14, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

NCT00579566
View directory record Official record
Conditions
Sarcoma
Interventions
Specimen protocol
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 14, 2026, 4:53 AM EDT
Completed No phase listed Observational

Penile Injection Anxiety

NCT00582231
View directory record Official record
Conditions
Penile Injection Therapy, Erectile Dysfunction, Radical Pelvic Surgery
Interventions
Questionnaires.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 14, 2026, 4:53 AM EDT